Literature DB >> 22895799

The out-of-focus bias in drug surveillance.

Markus Gnädinger1, Hans-Ulrich Mellinghoff.   

Abstract

PURPOSE: Existing drug safety systems with phase II and III studies and post-marketing surveillance by principle do not allow for the recognition of an important class of adverse drug reactions (ADRs). ADRs that are resistant to being detected reliably may a) appear as if they are age-related chronic diseases, which also manifest themselves in a high degree without drug treatment, b) arise in "old" drugs, c) arise during long-term application, and d) arise with the administration to frail and aged populations.
CONCLUSIONS: "Silent" and multi-factorial health problems evolving from long-term drug treatment must therefore be addressed with a systematic search strategy, as a third track along with the phase II and III studies and spontaneous reporting systems which still exist.

Entities:  

Mesh:

Year:  2012        PMID: 22895799     DOI: 10.1007/s00228-012-1371-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Attitudinal survey of voluntary reporting of adverse drug reactions.

Authors:  I A Eland; K J Belton; A C van Grootheest; A P Meiners; M D Rawlins; B H Stricker
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  Developing the Sentinel System--a national resource for evidence development.

Authors:  Rachel E Behrman; Joshua S Benner; Jeffrey S Brown; Mark McClellan; Janet Woodcock; Richard Platt
Journal:  N Engl J Med       Date:  2011-01-12       Impact factor: 91.245

3.  Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg).

Authors:  Kuanrong Li; Rudolf Kaaks; Jakob Linseisen; Sabine Rohrmann
Journal:  Heart       Date:  2012-06       Impact factor: 5.994

Review 4.  Parkinson's disease and the bones.

Authors:  Markus Gnädinger; Hans-Ulrich Mellinghoff; Alain Kaelin-Lang
Journal:  Swiss Med Wkly       Date:  2011-02-16       Impact factor: 2.193

Review 5.  A plea for a more epidemiological and patient-oriented pharmacovigilance.

Authors:  Veronica Scurti; Marilena Romero; Gianni Tognoni
Journal:  Eur J Clin Pharmacol       Date:  2011-07-20       Impact factor: 2.953

6.  Homocysteine as a predictive factor for hip fracture in older persons.

Authors:  Robert R McLean; Paul F Jacques; Jacob Selhub; Katherine L Tucker; Elizabeth J Samelson; Kerry E Broe; Marian T Hannan; L Adrienne Cupples; Douglas P Kiel
Journal:  N Engl J Med       Date:  2004-05-13       Impact factor: 91.245

7.  Homocysteine levels and the risk of osteoporotic fracture.

Authors:  Joyce B J van Meurs; Rosalie A M Dhonukshe-Rutten; Saskia M F Pluijm; Marjolein van der Klift; Robert de Jonge; Jan Lindemans; Lisette C P G M de Groot; Albert Hofman; Jacqueline C M Witteman; Johannes P T M van Leeuwen; Monique M B Breteler; Paul Lips; Huibert A P Pols; André G Uitterlinden
Journal:  N Engl J Med       Date:  2004-05-13       Impact factor: 91.245

Review 8.  Pharmacovigilance: methods, recent developments and future perspectives.

Authors:  L Härmark; A C van Grootheest
Journal:  Eur J Clin Pharmacol       Date:  2008-06-04       Impact factor: 2.953

Review 9.  Under-reporting of adverse drug reactions : a systematic review.

Authors:  Lorna Hazell; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

10.  The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin.

Authors:  Gandhi N Solayar; Pauline M Walsh; Kevin J Mulhall
Journal:  BMC Musculoskelet Disord       Date:  2011-10-28       Impact factor: 2.362

View more
  1 in total

1.  Medication incidents in primary care medicine: protocol of a study by the Swiss Federal Sentinel Reporting System.

Authors:  Markus Gnädinger; Alessandro Ceschi; Dieter Conen; Lilli Herzig; Milo Puhan; Alfred Staehelin; Marco Zoller
Journal:  BMJ Open       Date:  2015-04-23       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.